PRKAA2 and Hepatic steatosis: Simultaneously, the AMPK activator AICAR exhibited an effect comparable with CSF, while these effects induced by CSF were abolished by the AMPK inhibitor [29], which suggested that CSF might be a possible agent for hepatic steatosis therapy via targeting AMPK-dependent signal cascades.